Outcome of Patients with ALK plus NSCLC and Brain Metastases in Relation to Disease Burden and Clinical Management

被引：0
|
作者：
De Petris, Luigi [1 ]
Friesland, Signe [1 ]
Brodin, Daniel [2 ]
Carstens, Hanna [1 ]
Falkenius, Johan [1 ]
Grundberg, Oscar [2 ]
Lofdahl, Magnus [2 ]
Helleday, Clara Lenneby [1 ]
Karimi, Reza [2 ]
Ojdahl-Boden, Anna [2 ]
Tsakonas, Georgios [1 ]
Ekman, Simon [1 ]
Kolbeck, Karl-Gustav [2 ]
机构：
[1] Karolinska Univ Hosp, Oncol, Stockholm, Sweden
[2] Karolinska Univ Hosp, Resp Med & Allergol, Stockholm, Sweden
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
ALK; WBRT; CNS Metastasis; 2nd generation ALKi;
D O I：
10.1016/j.jtho.2016.11.1294
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.03b-013
引用
收藏
页码：S940 / S941
页数：2
相关论文
共 50 条
  • [41] Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
    Lee, Siow Ming
    Lewanski, Conrad R.
    Counsell, Nicholas
    Ottensmeier, Christian
    Bates, Andrew
    Patel, Nirali
    Wadsworth, Christina
    Ngai, Yenting
    Hackshaw, Allan
    Faivre-Finn, Corinne
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (07):
  • [42] Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy
    Lau, Sally C. M.
    Poletes, Christopher
    Le, Lisa W.
    Mackay, Kate M.
    Fares, Aline Fusco
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Tsao, Ming Sound
    Leighl, Natasha B.
    Liu, Geoffrey
    Shultz, David
    Sacher, Adrian G.
    LUNG CANCER, 2021, 156 : 76 - 81
  • [43] Targeted therapy with or without Radiotherapy in EGFR/ALK mutant NSCLC with Brain Metastases
    Ciscar Garcia, I.
    Martin Martin, M.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S742 - S742
  • [44] Whole brain radiotherapy in patients with NSCLC and brain metastases
    Le Pechoux, Cecile
    Dhermain, Frederic
    Besse, Benjamin
    LANCET, 2016, 388 (10055): : 1960 - 1962
  • [45] Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors
    Wu, Yanyu
    Ren, Kaili
    Wan, Yin
    Lin, Huamao M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (06) : 1418 - 1427
  • [46] The Cumulative Incidence of Brain Metastases in US Medicare Patients with ALK plus mNSCLC Treated with Second-generation ALK TKIs
    Bazhenova, L.
    Abrahami, D.
    Ramaswamy, K.
    Li, B.
    Davis, M.
    Epstein, A. J.
    Marcum, Z. A.
    Rifi, N.
    Kelton, J.
    Duncan, K.
    Uprety, D.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S711 - S712
  • [47] Economic burden in patients with ALK plus non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors
    Lin, Huamao M.
    Pan, Xiaoyun
    Hou, Peijie
    Huang, Hui
    Wu, Yanyu
    Ren, Kaili
    Jahanzeb, Mohammad
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (08) : 894 - 901
  • [48] Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC
    Addeo, Raffaele
    Zappavigna, Silvia
    Luce, Amalia
    Facchini, Sergio
    Caraglia, Michele
    EXPERT OPINION ON DRUG SAFETY, 2013, 12 (05) : 729 - 740
  • [49] Clinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases
    Slutzky-Shraga, Ilana
    Gorshtein, Alex
    Popovitzer, Aharon
    Robenshtok, Eyal
    Tsvetov, Gloria
    Akirov, Amit
    Hirsch, Dania
    Benbassat, Carlos
    ONCOLOGY LETTERS, 2018, 15 (01) : 672 - 676
  • [50] Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK plus NSCLC in the US
    Wan, Y.
    Ren, K.
    Lin, H. M.
    Wu, Y.
    Humphries, M. J.
    Zhang, P.
    Jahanzeb, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S478 - S479
12345